Damian Rieke

2.5k total citations · 1 hit paper
42 papers, 402 citations indexed

About

Damian Rieke is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Damian Rieke has authored 42 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cancer Research, 17 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Damian Rieke's work include Cancer Genomics and Diagnostics (22 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Damian Rieke is often cited by papers focused on Cancer Genomics and Diagnostics (22 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Damian Rieke collaborates with scholars based in Germany, United States and France. Damian Rieke's co-authors include Ulrich Keilholz, Ulf Leser, Manuela Benary, Dieter Beule, Max Schmidt, Georg Hilfenhaus, Maren Knödler, Ulrich Keller, Konrad Klinghammer and Dominik Soll and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Damian Rieke

35 papers receiving 395 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leveraging Large Language Models for Decision Support in Personalized Oncology

2023 139 citations Manuela Benary, Max Schmidt et al. profile →

Peers

Damian Rieke

MB

CR

AI

ONCOL

HI

Felipe Batalini United States

Yijun Wu China

Mingxuan Xie China

Peter Gershkovich United States

Yeqian Feng China

Visnja Fink Germany

Saba Shafi United States

Tobias Paul Seraphin Germany

Hyo Jung Hong South Korea

Mani Nassir Germany

Felipe Batalini United States

Damian Rieke

122 ×0.9

MB

76 ×0.7

CR

49 ×0.5

AI

186 ×2.0

ONCOL

48 ×0.5

HI

Citations per year, relative to Damian Rieke Damian Rieke (= 1×) peers Felipe Batalini

Countries citing papers authored by Damian Rieke

Since Specialization

Citations

This map shows the geographic impact of Damian Rieke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damian Rieke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damian Rieke more than expected).

Fields of papers citing papers by Damian Rieke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damian Rieke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damian Rieke. The network helps show where Damian Rieke may publish in the future.

Co-authorship network of co-authors of Damian Rieke

This figure shows the co-authorship network connecting the top 25 collaborators of Damian Rieke. A scholar is included among the top collaborators of Damian Rieke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damian Rieke. Damian Rieke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Rieke, Damian, Michael Bitzer, Annalen Bleckmann, et al.. (2025). Precision oncology – Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology. European Journal of Cancer. 220. 115331–115331.

2.

Qi, Changsong, Lin Shen, Thierry André, et al.. (2025). Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. European Journal of Cancer. 220. 115338–115338. 5 indexed citations

3.

Eich, Marie‐Lisa, Georg Hilfenhaus, Bernhard Ralla, et al.. (2024). Solitary fibrous tumor of the prostate with accompanying low-grade prostate cancer. Urology Case Reports. 57. 102879–102879.

4.

Habringer, Stefan, Jana Ihlow, Max Schmidt, et al.. (2024). A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass. The Oncologist. 29(10). 908–912.

5.

Silveira, André Bortolini, Alexandre Houy, Olivier Ganier, et al.. (2024). Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes. Nature Communications. 15(1). 9864–9864. 5 indexed citations

6.

Rieke, Damian, et al.. (2024). Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis. SHILAP Revista de lepidopterología. 2024. 1–6.

7.

Heilig, Christoph E., Alexander Desuki, Thomas Kindler, et al.. (2024). 198P Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial. Annals of Oncology. 35. S295–S296. 1 indexed citations

8.

Rieke, Damian, Manuela Benary, Peter Horak, et al.. (2023). Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts.. Journal of Clinical Oncology. 41(16_suppl). 3066–3066. 1 indexed citations

9.

Rieke, Damian, Philippe Schafhausen, Eric Blanc, et al.. (2023). Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma. Frontiers in Oncology. 13. 1107134–1107134. 5 indexed citations

10.

Schlenk, Richard F., Małgorzata Oleś, Sebastian Bauer, et al.. (2023). 1940P Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials. Annals of Oncology. 34. S1042–S1042.

11.

Heilig, Christoph E., Jennifer Hüllein, Mandeep Singh, et al.. (2023). 2318P Value of broad molecular profiling for cancer diagnosis. Annals of Oncology. 34. S1184–S1184. 1 indexed citations

12.

Rieke, Damian, Christian Doll, Annekatrin Coordes, et al.. (2023). Prognostic factors in surgically treated malignant salivary gland tumors. Oral Oncology. 144. 106484–106484. 4 indexed citations

13.

Obermayer, Benedikt, Konrad Klinghammer, Sebastian Ochsenreither, et al.. (2020). Distinct immune evasion in APOBEC ‐enriched, HPV ‐negative HNSCC. International Journal of Cancer. 147(8). 2293–2302. 12 indexed citations

14.

Lamping, Mario, Manuela Benary, Serge Leyvraz, et al.. (2020). Support of a molecular tumour board by an evidence-based decision management system for precision oncology. European Journal of Cancer. 127. 41–51. 16 indexed citations

15.

Leyvraz, Serge, Mieke Schutte, Torsten Keßler, et al.. (2020). 1142P Treatment of metastatic uveal melanoma (mUM) through genomic profiling. Annals of Oncology. 31. S764–S764.

16.

Barnell, Erica K., Adam Waalkes, Kelsi Penewit, et al.. (2019). Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes. JCO Clinical Cancer Informatics. 3(3). 1–12. 6 indexed citations

17.

Starlinger, Johannes, Jurica Ševa, Damian Rieke, et al.. (2018). Variant information systems for precision oncology. BMC Medical Informatics and Decision Making. 18(1). 107–107. 5 indexed citations

18.

Rieke, Damian, Serge Leyvraz, Susen Burock, & Ulrich Keilholz. (2017). A comparison of treatment recommendations by molecular tumor boards worldwide. Annals of Oncology. 28. v40–v40. 4 indexed citations

19.

Rieke, Damian, Konrad Klinghammer, & Ulrich Keilholz. (2016). Targeted Therapy of Head and Neck Cancer. Oncology Research and Treatment. 39(12). 780–786. 13 indexed citations

20.

Endhardt, Katharina, Arun Khattri, Michaela K. Keck, et al.. (2014). Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence on PI3K signaling and resistance to EGFR inhibition.. Journal of Clinical Oncology. 32(15_suppl). 6034–6034. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact